Targeted therapies in colorectal cancer—an integrative view by PPPM

[1]  J. Hurley,et al.  The molecular genetics of colorectal cancer , 2013, Frontline Gastroenterology.

[2]  A. Lièvre,et al.  Role of microsatellite instability in the management of colorectal cancers. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  V. Heinemann,et al.  Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group , 2013, International journal of cancer.

[4]  Ken Kato,et al.  Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer , 2013, International Journal of Clinical Oncology.

[5]  M. Parmar,et al.  Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. , 2012, Cancer treatment reviews.

[6]  A. Zullo,et al.  Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer , 2012, OncoTargets and therapy.

[7]  P. Shekelle,et al.  Screening for Colorectal Cancer , 2012, Annals of Internal Medicine.

[8]  M. Stratton,et al.  Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes , 2012, The Journal of pathology.

[9]  R. Goldberg,et al.  Cost‐effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany , 2012, International journal of cancer.

[10]  P. Carmeliet,et al.  VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. , 2012, The Lancet. Oncology.

[11]  E. Bandrés,et al.  Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients , 2012, British Journal of Cancer.

[12]  J. Mariadason,et al.  PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. , 2012, Clinical colorectal cancer.

[13]  E. Scarpi,et al.  Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study , 2012, Journal of Translational Medicine.

[14]  A. Grothey,et al.  Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. , 2012, European journal of cancer.

[15]  D. Cunningham,et al.  Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection , 2012, British Journal of Cancer.

[16]  B. Chauffert,et al.  Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  I. Grundberg,et al.  Methods for analysis of the cancer microenvironment and their potential for disease prediction, monitoring and personalized treatments , 2012, EPMA Journal.

[18]  Levi Waldron,et al.  Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum , 2012, Gut.

[19]  C. Tinelli,et al.  Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer , 2012, Journal of Cancer Research and Clinical Oncology.

[20]  G. Tortora,et al.  Clinical impact of anti‐epidermal growth factor receptor monoclonal antibodies in first‐line treatment of metastatic colorectal cancer , 2012, Cancer.

[21]  T. Fennell,et al.  Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.

[22]  A. Adler,et al.  NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy. , 2012, The Lancet Oncology.

[23]  M. Arends,et al.  Molecular typing of colorectal cancer: applications in diagnosis and treatment , 2012 .

[24]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[25]  F. Fostira,et al.  Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab , 2011, The Pharmacogenomics Journal.

[26]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .

[27]  C. la Vecchia,et al.  Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety. , 2012, The oncologist.

[28]  H. Lenz,et al.  Assessing the in vivo efficacy of biologic antiangiogenic therapies , 2012, Cancer Chemotherapy and Pharmacology.

[29]  Nikhil Wagle,et al.  High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.

[30]  Tae Won Kim,et al.  Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status , 2012, Investigational New Drugs.

[31]  M. Lacouture,et al.  The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. , 2011, Clinical colorectal cancer.

[32]  J. Gaudart,et al.  Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer , 2011, BMC Cancer.

[33]  I. Zlobec,et al.  Comprehensive analysis of CpG island methylator phenotype (CIMP)‐high, ‐low, and ‐negative colorectal cancers based on protein marker expression and molecular features , 2011, The Journal of pathology.

[34]  J. Meyerhardt,et al.  Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. , 2011, The Journal of clinical investigation.

[35]  E. Sabo,et al.  Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer , 2011, Virchows Archiv.

[36]  M. Konstadoulakis,et al.  The continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer offers a survival benefit. , 2011, Hepato-Gastroenterology.

[37]  W. Samowitz,et al.  Epidermal growth factor receptor pathway mutations and colorectal cancer therapy. , 2011, Archives of pathology & laboratory medicine.

[38]  Y. Ba,et al.  Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial , 2011, Chinese journal of cancer.

[39]  S. Matsusaka,et al.  Circulating endothelial progenitors and CXCR4‐positive circulating endothelial cells are predictive markers for bevacizumab , 2011, Cancer.

[40]  A. Pollett,et al.  Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer. , 2011, Current oncology.

[41]  H. Moch,et al.  KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective , 2011, Clinical Cancer Research.

[42]  O. Carpén,et al.  EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer , 2011, British Journal of Cancer.

[43]  G. Webersinke,et al.  Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases. , 2011, Pathology, research and practice.

[44]  Brandon Whitcher,et al.  DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6 , 2011, British Journal of Cancer.

[45]  M. Pino,et al.  Microsatellite instability in the management of colorectal cancer , 2011, Expert review of gastroenterology & hepatology.

[46]  Elizabeth M Webber,et al.  Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. , 2011, American journal of cancer research.

[47]  O. Nordgård,et al.  Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy , 2011, International Journal of Colorectal Disease.

[48]  Rugang Zhang,et al.  Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. , 2011, Molecular cell.

[49]  J. Cubiella,et al.  5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. , 2011, Gastroenterology.

[50]  M. Mazzone,et al.  Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. , 2011, Molecular aspects of medicine.

[51]  P. Quirke,et al.  Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing , 2011, Analytical cellular pathology.

[52]  F. Coppedè,et al.  Genetics, Cytogenetics, and Epigenetics of Colorectal Cancer , 2011, Journal of biomedicine & biotechnology.

[53]  E. Maiello,et al.  Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. , 2011, The oncologist.

[54]  S. Matsusaka,et al.  Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer , 2011, Cancer Chemotherapy and Pharmacology.

[55]  Hong Ding,et al.  BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis , 2011, Molecular Biology Reports.

[56]  K. Shirouzu,et al.  Characteristics of recurrence after curative resection for T1 colorectal cancer: Japanese multicenter study , 2011, Journal of Gastroenterology.

[57]  A. Harris,et al.  Biomarkers to predict the clinical efficacy of bevacizumab in cancer. , 2010, The Lancet. Oncology.

[58]  M. Saif,et al.  Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. , 2010, Clinical colorectal cancer.

[59]  I. Nagtegaal,et al.  The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  C. Tinelli,et al.  Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  H. Kennecke,et al.  Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer. , 2010, Current oncology.

[63]  O. Delattre,et al.  Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. , 2010, Anticancer research.

[64]  A. Lièvre,et al.  Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti‐EGFR antibodies in colorectal cancer , 2010, International journal of cancer.

[65]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[66]  D. Characiejus,et al.  “First do no harm” and the importance of prediction in oncology , 2010, EPMA Journal.

[67]  Barry S Taylor,et al.  Genomic and biological characterization of exon 4 KRAS mutations in human cancer. , 2010, Cancer research.

[68]  C. Punt,et al.  Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. , 2010, European journal of cancer.

[69]  I. Nagtegaal,et al.  Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. , 2010, European journal of cancer.

[70]  Jeffrey W. Clark,et al.  Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. , 2010, The oncologist.

[71]  G. Sledge,et al.  Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). , 2010 .

[72]  P. Hegde,et al.  Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies. , 2010 .

[73]  Anwar R. Padhani,et al.  Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[74]  M. Sticherling,et al.  Cutaneous side effects of inhibition of VEGF signal transduction , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[75]  T. George,et al.  Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. , 2010, The journal of supportive oncology.

[76]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[77]  J. Schiller,et al.  Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  N. Magné,et al.  Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab. , 2010, Bulletin du cancer.

[79]  K. Schaefer,et al.  Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases , 2010, Clinical Cancer Research.

[80]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  G. Pedrazzi,et al.  PTEN status in advanced colorectal cancer treated with cetuximab , 2009, British Journal of Cancer.

[82]  M. Sticherling,et al.  Cutaneous side effects of inhibition of VEGF signal transduction , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[83]  Jeffrey W. Clark,et al.  Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. , 2010, The Lancet. Oncology.

[84]  A. Jimeno,et al.  KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. , 2010, The Journal of molecular diagnostics : JMD.

[85]  Josep Tabernero,et al.  EGFR and KRAS in colorectal cancer. , 2010, Advances in clinical chemistry.

[86]  J. Reid,et al.  Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[88]  T. Mok,et al.  A small step towards personalized medicine for non-small cell lung cancer. , 2009, Discovery medicine.

[89]  L. Mazzucchelli,et al.  Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.

[90]  J. Meyerhardt,et al.  Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer , 2009, British Journal of Cancer.

[91]  N. Funel,et al.  PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  R. Perez-soler,et al.  Skin toxicities associated with epidermal growth factor receptor inhibitors , 2009, Targeted Oncology.

[93]  J. Lindebjerg,et al.  The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  B. Uzzan,et al.  Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. , 2009, Anticancer research.

[95]  E. Benjamin,et al.  Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function. , 2009, European heart journal.

[96]  D. Lambrechts,et al.  PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer , 2009, Clinical Cancer Research.

[97]  M. Somerfield,et al.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  E. Van Cutsem,et al.  Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy , 2009, Cancer.

[99]  Francesca Molinari,et al.  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.

[100]  H. Joensuu,et al.  Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[101]  R. Berardi,et al.  Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[102]  S. Andreola,et al.  PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[103]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  E. Perez,et al.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[106]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[107]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[108]  D. Sargent,et al.  Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer , 2008, Clinical Cancer Research.

[109]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  V. Catalano,et al.  Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  G. Israel,et al.  Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. , 2008, Clinical colorectal cancer.

[113]  C. Ensinger,et al.  Implications of EGFR PharmDx™ Kit for cetuximab eligibility , 2008, Expert review of molecular diagnostics.

[114]  Li Zhao,et al.  Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms , 2008, Proceedings of the National Academy of Sciences.

[115]  Sunghuen Kim,et al.  A Report of Two Cases , 2008 .

[116]  E. Van Cutsem,et al.  Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab , 2007, British Journal of Cancer.

[117]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[118]  Wei Chen,et al.  Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  F. Cavalli,et al.  PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.

[120]  J. Berlin,et al.  Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials , 2007 .

[121]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[123]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[124]  J. Jass.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features , 2007, Histopathology.

[125]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[126]  M. Saif,et al.  Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. , 2006, Anti-cancer drugs.

[127]  E. Van Cutsem,et al.  Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  Sarah Edkins,et al.  Recurrent KRAS codon 146 mutations in human colorectal cancer , 2006, Cancer biology & therapy.

[129]  A. Grothey,et al.  Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. , 2006, Clinical colorectal cancer.

[130]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[131]  B. Vincenzi,et al.  Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial , 2006, British Journal of Cancer.

[132]  J. Hecht,et al.  A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. , 2006, Clinical colorectal cancer.

[133]  E. Vokes,et al.  Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G) , 2005 .

[134]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  Richard L Schilsky,et al.  Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.

[136]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[137]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[138]  C. Compton,et al.  Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. , 2004, Cancer research.

[139]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  이석호,et al.  Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.

[141]  J. Hughes,et al.  First Do No Harm: Adverse Effects of Grouping Deviant Youth for Skills Training , 1999 .

[142]  A. Norman,et al.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.

[143]  A. Norman,et al.  K-ras mutations in patients with early colorectal cancers , 1997, Gut.

[144]  D A Redelmeier,et al.  Screening for colorectal cancer. , 1995, The New England journal of medicine.

[145]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[146]  R. Kucherlapati,et al.  Genetic analysis of epidermal growth factor action: assignment of human epidermal growth factor receptor gene to chromosome 7. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[147]  J. Folkman,et al.  ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS , 1971, The Journal of experimental medicine.